Neuland Laboratories Q4FY26: PAT surge, Rs 34 dividend

Results update and key announcements

Neuland Laboratories Ltd. reported a sharp rise in consolidated profitability for Q4FY26, supported by strong demand across global markets. Alongside the earnings update, the company’s Board recommended a final dividend and cleared a capacity enhancement plan in Telangana. The set of announcements also included corporate actions related to the Annual General Meeting (AGM) calendar and a board-level appointment.

The company’s stock was reported at different points in time in the provided disclosures. Neuland Laboratories’ share price was listed at Rs 13,110 on 02 Feb, 2026 at 09:54 AM IST, down 3.17% from Rs 13,251. Separately, a last traded price of Rs 13,117 was also cited. Later, a “Current Price” of Rs 18,087 was mentioned for 29 Jun at 4:01 p.m.

Q4FY26: revenue and income jumped year-on-year

For Q4FY26, revenue from operations was reported at Rs 776.25 crore (Rs 77,625.03 lakh). This was up 76.54% sequentially from Rs 439.71 crore (Rs 43,970.93 lakh) in Q3FY26 and up 136.40% year-on-year from Rs 328.36 crore (Rs 32,836.00 lakh) in Q4FY25.

Total income for Q4FY26 stood at Rs 788.71 crore (Rs 78,870.85 lakh). The company reported this as a 76.14% QoQ increase from Rs 447.76 crore (Rs 44,776.17 lakh) and a 134.86% YoY increase from Rs 335.82 crore (Rs 33,582.43 lakh) in Q4FY25.

These numbers align with a separate disclosure stating consolidated revenue from operations of Rs 776.25 crore in Q4FY26 versus Rs 328.36 crore in Q4FY25, a 136.3% YoY rise.

Q4FY26 profitability: PAT and PBT moved sharply higher

Profit after tax (PAT) for Q4FY26 was reported at Rs 212.67 crore (Rs 21,267.26 lakh). This represented 424.18% growth QoQ from Rs 40.57 crore (Rs 4,057.19 lakh) in Q3FY26, and 664.85% growth YoY from Rs 27.81 crore (Rs 2,780.59 lakh) in Q4FY25.

Profit before tax (PBT) for Q4FY26 was reported at Rs 287.49 crore, compared with Rs 39.30 crore in Q4FY25, a 631.5% YoY increase as stated in the disclosure.

FY26 performance: higher income and earnings

For the year ended March 31, 2026, revenue from operations was reported at Rs 2,022.99 crore (Rs 2,02,298.54 lakh), up 36.98% from Rs 1,476.84 crore (Rs 1,47,683.73 lakh) in FY25. Total income for FY26 stood at Rs 2,053.15 crore (Rs 2,05,315.16 lakh), compared with Rs 1,497.35 crore (Rs 1,49,734.66 lakh) in FY25, an increase of 37.12%.

FY26 consolidated PAT was reported at Rs 364.00 crore (Rs 36,399.84 lakh), up 39.94% from Rs 260.11 crore (Rs 26,010.81 lakh) in FY25. Total comprehensive income for FY26 was reported at Rs 365.06 crore (Rs 36,506.25 lakh) versus Rs 260.06 crore (Rs 26,006.33 lakh) in FY25.

PBT for FY26 was reported at Rs 488.98 crore compared to Rs 346.33 crore in FY25, a 41.2% YoY increase. Earnings per share (EPS) for FY26 stood at Rs 283.71 compared to Rs 202.74 in FY25.

Dividend, record date, and AGM schedule

The Board of Directors recommended a final dividend of Rs 34 per equity share (face value Rs 10) for FY26, subject to shareholder approval. The record date for determining shareholder eligibility for the dividend was fixed as July 24, 2026.

The company approved convening of its 42nd AGM on Tuesday, August 4, 2026. The AGM notice stated the meeting would be held at 10:00 a.m. (IST) through Video Conferencing (VC) or Other Audio Visual Means (OAVM). As per the disclosure, the dividend will be paid on or after five days from the date of declaration by shareholders at the AGM.

Capacity expansion: Unit-1 in Telangana

Neuland Laboratories approved a capacity enhancement at its Unit-1 facility in Bonthapally Village, Telangana. The company plans to add 120.5 KL capacity over the next 12 to 18 months. The planned investment was disclosed at around Rs 143.4 crore, to be funded through internal accruals and borrowings.

This expansion plan was disclosed alongside the strong Q4FY26 profitability update and forms a key operational development for FY27 execution timelines, based on the stated 12 to 18 month window.

Board actions and management updates

The Board also approved the appointment of Dr. Mauricio Futran as an Additional Director, classified as a Non-Executive Non-Independent Director, with effect from May 12, 2026. Separately, the AGM agenda included re-appointment of Dr. Davuluri Rama Mohan Rao (DIN: 00107737), who retires by rotation and being eligible offers himself for re-appointment.

A Board meeting date of Feb 9, 2026 was also referenced with the agenda listed as “Quarterly Results”, and a “Release Date: February 09, 2026” was cited in the provided material.

Other disclosed operating and financial datapoints

The provided disclosures also carried additional metrics and commentary tied to quarterly performance and cash flow. Working capital was stated at 145 days of sales outstanding. Capex cash outflow was stated at Rs 254 crore over the nine months of FY26.

Free cash flow for the year was stated as negative at Rs 9.2 crore, despite significant customer advances. Net debt was disclosed as negative Rs 202.6 crore, indicating a net cash position on that definition. India revenue was cited at Rs 121.50 crore.

Market snapshot and valuation metrics cited

The provided material included market and valuation indicators at a point in time: market cap of Rs 20,260 crore, ROE of 13.30%, P/E (TTM) of 115.02, EPS (TTM) of 137.29, P/B of 13.29, dividend yield of 0.08%, and book value of 1,187.77. The NSE symbol was listed as NEULANDLAB.

These indicators were presented as snapshot metrics and should be read alongside the company’s FY26 earnings and the corporate actions announced for the dividend and AGM.

Key numbers at a glance

Market impact and why the update matters

The Q4FY26 numbers represent a sharp step-up in both scale and profitability compared to Q4FY25, based on the reported year-on-year growth rates in revenue, total income, and PBT. The dividend recommendation and the record date provide a defined timeline for shareholder eligibility, while the AGM date sets a clear decision point for dividend approval.

Operationally, the Unit-1 capacity addition plan in Telangana is a concrete capex commitment with an indicated execution window of 12 to 18 months and a stated funding mix of internal accruals and borrowings. The disclosure of negative net debt and the capex cash outflow for nine months of FY26 adds context on balance sheet position and cash deployment during the year, as provided.

Conclusion

Neuland Laboratories closed FY26 with large reported gains in Q4 earnings and higher full-year revenue and profit compared with FY25. The next milestones disclosed are the record date on July 24, 2026 and the 42nd AGM on August 4, 2026, where the Rs 34 final dividend is slated for shareholder approval.